{
    "symbol": "DRRX",
    "quarter": 4,
    "year": 2022,
    "date": "2023-03-07 18:46:05",
    "content": " If successful, we believe AHFIRM has the potential to support an NDA filing. If successful, we believe AHFIRM has the potential to support an NDA filing. Well, we -- patients who have AH, there's over 85% or so have insurance, but one needs that in order to get a transplant pretty much. But in addition to that primary endpoint, obviously, there's a number of market access and reimbursement factors in the hospital that I think larsucosterol could help offset things like decreasing length of stay, decreasing diagnostics and health care -- other health care realization, hopefully, decreasing the time spent in ICU that these severe AH patients typically comprise."
}